Investor Presentation Q1 2023

42 Investor presentation First three months of 2023 SUSTAIN trials with subcutaneous semaglutide SUSTAIN 1 2 3 4 5 Baseline 8.1% 8.1% 8.3% 8.2% 8.4% 8.7% -0.1 Change in HbA1c (%) -0.5 -0.9 -0.8 6 7 * -1.3* * * -1.5 -1.6 -1.6* -1.5* -1.2' * -1.1 * -1.4* -1.4* -1.6* -1.8 1.2 89 kg 96 kg 93 kg 92 kg 92 kg 92 kg Baseline Change in weight (kg) -3.7 -4.5* -1 -1.9 -1.9 -4.3 -5.2 * -1.4 * -3.5 -3.7* * -4.9 -3.6 -0.4 -0.7 8.2% -1.8-1.5 -1.1 -1.3 95 kg -4.6 * Novo NordiskⓇ -2.3 -3.0 * -5.6 -6.1 * | semaglutide 1.0 mg semaglutide 0.5 mg placebo -6.4* sitagliptin 100 mg exenatide ER glargine U100 dulaglutide 1.5 mg -6.5* dulaglutide 0.75 mg * Statistically significant; SUSTAIN 1: QW sema vs placebo in drug-naïve people with T2D; SUSTAIN 2: QW sema vs sitagliptin 100 mg QD in people with T2D added to 1-2 OADS; SUSTAIN 3: QW sema vs QW exenatide ER 2.0 mg in people with T2D added to 1-2 OADS; SUSTAIN 4: QW sema vs QD insulin glargine in people with T2D added to 1-2 OADS; SUSTAIN 5: QW sema vs placebo in people with T2D added to insulin; SUSTAIN 6: QW sema vs placebo, added to standard-of-care; SUSTAIN 7: QW sema vs QW dulaglutide 75 mg and 150 mg in people with T2D added to 1-2 OADS: ER: Extended-release; QW: once-weekly; QD: once-daily; sema: semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabetics

View entire presentation